Skip to content
value.today
UroGen Pharma Ltd. logo

UroGen Pharma Ltd.

UroGen Pharma Ltd. is listed today as UroGen Pharma Ltd.: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of UroGen Pharma Ltd.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2023$120 MPrivate placement after listing$50 to $250 million

UroGen Pharma Ltd.: Private sale, Jul 2023

Investors in this round

8 investors had bought by the notice of Aug 14, 2023: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$120 M of $120 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Equity offering includes Ordinary Shares and Pre-Funded Warrants to purchase Ordinary Shares and Ordinary Shares issuable upon the exercise of Pre-Funded Warrants.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$3,240,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Israel

People named in the notice

  • Don Kim · Executive Officer
  • Elizabeth Barrett · Executive Officer, Director
  • Jason A. Smith · Executive Officer
  • Mark A. Schoenberg, M.D. · Executive Officer
  • Arie Belldegrun, M.D. · Director
  • Cynthia Butitta · Director
  • Dan Wildman · Director
  • Fred Cohen, M.D. · Director
  • James A. Robinson, Jr. · Director
  • Leana Wen, M.D., MSc · Director
  • Ran Nussbaum · Director
  • Stuart Holden, M.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in CT, MA, NY, PA, TX
  • BofA Securities, Inc. (CRD 283942) · New York, New YorkSold in CT, MA, NY, PA, TX

Signed by Don Kim, Chief Financial Officer. Source: SEC Form D, newest notice filed Aug 14, 2023. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company UroGen Pharma Ltd., its revenue in fiscal 2025 came from these product and service lines: Jelmyto $93.99 million (86%), Zusduri $15.80 million (14%).

    Annual report (SEC XBRL) · Dec 2025

  • UroGen Pharma Ltd. chose not to state its revenue in its newest notice of a funding round (Aug 2023).

    SEC Form D · Aug 2023

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Aug 2023

Products and services#

No products or services of UroGen Pharma Ltd. are on record.

Investors#

No investor of UroGen Pharma Ltd. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.

Largest shareholders today

Institutions holding UroGen Pharma Ltd. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by UroGen Pharma Ltd.
NameRoleNamed in
Don KimExecutive officerAug 2023
Elizabeth BarrettExecutive officerAug 2023
Jason A. SmithExecutive officerAug 2023
Mark A. Schoenberg, M.D.Executive officerAug 2023
Arie Belldegrun, M.D.DirectorAug 2023
Cynthia ButittaDirectorAug 2023
Dan WildmanDirectorAug 2023
Elizabeth BarrettDirectorAug 2023
Fred Cohen, M.D.DirectorAug 2023
James A. Robinson, Jr.DirectorAug 2023
Leana Wen, M.D., MScDirectorAug 2023
Ran NussbaumDirectorAug 2023
Stuart Holden, M.D.DirectorAug 2023

Went public since 2017. Its SEC number is that of a company listed on a stock exchange.